Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
Ruggero CapraVincenzo Brescia MorraMassimiliano MirabellaClaudio GasperiniCinzia ScandellariRocco TotaroNicola De RossiSilvia MaseraValentina ZipoliFrancesco Pattinull nullPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2020)
The reductions in Absenteeism and Work Productivity Loss and the improved physical and psychological functioning reported after 1 year of natalizumab treatment in real-world settings extend our understanding of natalizumab's effects on patient-centric and health economics outcomes.
Keyphrases
- multiple sclerosis
- white matter
- end stage renal disease
- mental health
- newly diagnosed
- ejection fraction
- chronic kidney disease
- public health
- prognostic factors
- climate change
- peritoneal dialysis
- case report
- rheumatoid arthritis
- risk assessment
- skeletal muscle
- systemic lupus erythematosus
- weight loss
- smoking cessation